NEW YORK (GenomeWeb News) – CombiMatrix today said that oral arguments in its ongoing litigation with National Union Fire Insurance will be heard on Feb. 2.

The microarray and molecular diagnostics firm said that the hearing will be held at the Ninth Circuit Court of Appeals in Pasadena, Calif., and each side will have 15 minutes to make arguments in support of briefs that were filed earlier.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.